Medicare Enrolled
Dr. John Schaub, DO
Hematology & Oncology · Pensacola, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Schaub from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Schaub? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Schaub
Dr. John Schaub is a hematology & oncology in Pensacola, FL, with 9 years in practice. Based on federal Medicare data, Dr. Schaub performed 141,277 Medicare services across 2,566 unique beneficiaries.
Between the years covered by Open Payments, Dr. Schaub received a total of $6,777 from 63 pharmaceutical and/or device companies across 269 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Schaub is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 9 years in practice▲ Top 4% volume in FL$ $6,777 industry payments
Medicare Practice Summary
Medicare Utilization ↗141,277
Medicare services
Top 4% in FL for hematology & oncology
2,566
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~15,697 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim injection (Nivestym) for white blood cells | 19,620 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 19,200 | $43 | $131 |
| Iron infusion (Feraheme) | 18,360 | $0 | $6 |
| Darbepoetin injection (Aranesp) for anemia | 12,850 | $2 | $21 |
| Anti-nausea injection (fosaprepitant) | 11,550 | $0 | $6 |
| Azacitidine chemotherapy injection | 11,501 | $0 | $14 |
| Nivolumab injection (Opdivo) | 9,060 | $24 | $74 |
| Oxaliplatin chemotherapy injection | 8,600 | $0 | $36 |
| Paclitaxel chemotherapy injection | 7,550 | $0 | $1 |
| Contrast dye for imaging (iodine-based) | 3,660 | $0 | $3 |
| Anti-nausea injection (aprepitant) | 3,250 | $1 | $8 |
| Denosumab injection (Prolia/Xgeva) | 2,520 | $18 | $46 |
| Iron infusion (Monoferric) | 2,500 | $17 | $71 |
| Dexamethasone injection (steroid) | 1,676 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia | 1,580 | $6 | $30 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,330 | $1 | $122 |
| Office visit, established patient (30-39 min) | 792 | $95 | $224 |
| Injection, granisetron hydrochloride, 100 mcg | 600 | $0 | $25 |
| Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 468 | $94 | $157 |
| Injection of additional new drug or substance into vein | 464 | $11 | $105 |
| Injection, leucovorin calcium, per 50 mg | 436 | $2 | $27 |
| Administration of chemotherapy into vein, 1 hour or less | 414 | $93 | $686 |
| Injection, carboplatin, 50 mg | 396 | $2 | $300 |
| Injection, fluorouracil, 500 mg | 283 | $1 | $10 |
| Drug injection, under skin or into muscle | 269 | $11 | $93 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 218 | $21 | $152 |
| Office visit, established patient, complex (40-54 min) | 201 | $133 | $301 |
| New patient office visit (45-59 min) | 194 | $122 | $343 |
| Injection, magnesium sulfate, per 500 mg | 160 | $1 | $6 |
| Administration of additional new drug or substance into vein, 1 hour or less | 132 | $46 | $334 |
| Injection, gadobenate dimeglumine (multihance), per ml | 130 | $1 | $16 |
| Initial hospital admission, high complexity | 118 | $132 | $412 |
| Injection, zoledronic acid, 1 mg | 116 | $7 | $462 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 107 | $46 | $304 |
| Administration of chemotherapy into vein, each additional hour | 105 | $20 | $156 |
| Injection, diphenhydramine hcl, up to 50 mg | 101 | $1 | $5 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 73 | $52 | $205 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 67 | $4 | $26 |
| Administration of additional new drug or substance into vein using push technique | 56 | $42 | $281 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 55 | $15 | $97 |
| Office visit, established patient (20-29 min) | 55 | $67 | $148 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 55 | $401 | $638 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 54 | $1,166 | $4,120 |
| Hospital follow-up visit, high complexity | 45 | $93 | $232 |
| Hospital follow-up visit, moderate complexity | 35 | $61 | $157 |
| Infusion into a vein for hydration, 31-60 minutes | 32 | $25 | $249 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 30 | $26 | $141 |
| Infusion, normal saline solution , 1000 cc | 30 | $2 | $19 |
| Ct scan of chest with contrast | 26 | $90 | $1,005 |
| Irrigation of implanted venous access drug delivery device | 26 | $18 | $111 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 24 | $9 | $91 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 24 | $1 | $19 |
| CT scan of abdomen and pelvis with contrast | 21 | $202 | $1,400 |
| New patient office visit, complex (60-74 min) | 21 | $164 | $432 |
| Blood creatinine level | 20 | $5 | $30 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 17 | $130 | $986 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
15.1% high complexity
83.7% medium
1.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,777
Total received (2018-2024)
Avg $968/year across 7 years
Top 42% in FL for hematology & oncology
63
Companies
269
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,961 (87.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$817 (12.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,346
2023$981
2022$1,120
2021$1,533
2020$832
2019$876
2018$90
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$586
BeiGene USA, Inc.
$383
Incyte Corporation
$372
Astellas Pharma US Inc
$368
E.R. Squibb & Sons, L.L.C.
$342
AstraZeneca Pharmaceuticals LP
$299
Genentech USA, Inc.
$291
Novartis Pharmaceuticals Corporation
$265
PFIZER INC.
$237
Merck Sharp & Dohme LLC
$224
Lilly USA, LLC
$221
GENZYME CORPORATION
$204
Eisai Inc.
$202
Seagen Inc.
$196
Janssen Biotech, Inc.
$181
Celgene Corporation
$167
Regeneron Healthcare Solutions, Inc.
$165
Allergan, Inc.
$125
Blueprint Medicines Corporation
$124
Teva Pharmaceuticals USA, Inc.
$124
Alexion Pharmaceuticals, Inc.
$119
Medtronic, Inc.
$110
Blue Earth Diagnostics Limited
$110
Ipsen Biopharmaceuticals, Inc
$90
EMD Serono, Inc.
$82
Mallinckrodt LLC
$79
Mirati Therapeutics, Inc.
$78
Takeda Pharmaceuticals U.S.A., Inc.
$75
Karyopharm Therapeutics Inc.
$74
AbbVie Inc.
$64
Rigel Pharmaceuticals, Inc.
$60
TESARO, Inc.
$53
GlaxoSmithKline, LLC.
$43
Stemline Therapeutics Inc.
$40
PUMA BIOTECHNOLOGY, INC.
$37
Kyowa Kirin, Inc.
$32
Foundation Medicine, Inc.
$32
ADC Therapeutics America, Inc.
$31
Merck Sharp & Dohme Corporation
$30
Acceleron Pharma, Inc.
$29
Helsinn Therapeutics (U.S.), Inc.
$28
MorphoSys, US Inc.
$27
Puma Biotechnology, Inc.
$25
SECURA BIO, INC.
$24
Daiichi Sankyo Inc.
$24
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$23
Bayer Healthcare Pharmaceuticals Inc.
$22
Tempus AI, Inc
$21
Adaptive Biotechnologies Corporation
$18
Pharmacosmos Therapeutics Inc.
$18
Epizyme, Inc.,
$18
Bayer HealthCare Pharmaceuticals Inc.
$18
Pharmacyclics LLC, an AbbVie Company
$18
Seattle Genetics, Inc.
$17
Genmab U.S., Inc.
$17
Pharmacyclics LLC, An AbbVie Company
$17
Alnylam Pharmaceuticals Inc.
$16
Deciphera Pharmaceuticals Inc.
$16
Taiho Oncology, Inc.
$15
AbbVie, Inc.
$14
SpringWorks Therapeutics, Inc.
$13
TerSera Therapeutics LLC
$12
Servier Pharmaceuticals LLC
$11
Top 3 companies account for 19.8% of total payments
Associated products mentioned in payments ›
ADCETRIS · AJOVY · ALIMTA · ALUNBRIG · AYVAKIT · BLENREP · BOSULIF · BRUKINSA · Blincyto · CABLIVI · CALQUENCE · CELLEXXTS PHOTOPHERESIS SYSTEM · COPIKTRA · CYRAMZA · Columvi · DARZALEX · ELIQUIS · ELITEK · ENJAYMO · ERLEADA · EVENITY · EXKIVITY · Enhertu · Epkinly · FARXIGA · FOUNDATIONONE · Fabhalta · GIVLAARI · HAWKONE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · MVASI · NERLYNX · NINLARO · Nerlynx · Nplate · Nubeqa · OGSIVEO · OPDIVO · OPDUALAG · Orserdu · PADCEV · PLUVICTO · POSLUMA · POTELIGEO · PREVYMIS · PROMACTA · Pomalyst · Prolia · QINLOCK · REBLOZYL · Reblozyl · Rituxan · SARCLISA · SOLIRIS · SOMATULINE DEPOT · Stivarga · TAGRISSO · TALVEY · TAZVERIK · TECENTRIQ · TIBSOVO · Tavalisse · Tecentriq · Ultomiris · VALCHLOR · VENCLEXTA · VERZENIO · VRAYLAR · Venclexta · XGEVA · XIFAXAN · XOSPATA · XPOVIO · XT CDX · XTANDI · Xermelo · Xtandi · ZEJULA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (88%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $5 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
20
Per 100K population
6.2
County median income
$65,715
Nearest hospital
BAPTIST HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Schaub is a mixed practice specialist, with above-average Medicare volume (top 4% in FL), and low-engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Schaub experienced with filgrastim injection (nivestym) for white blood cells?
Based on Medicare claims data, Dr. Schaub performed 19,620 filgrastim injection (nivestym) for white blood cells services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Schaub receive payments from pharmaceutical companies?
Yes. Dr. Schaub received a total of $6,777 from 63 companies across 269 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Schaub's costs compare to other hematology & oncologys in Pensacola?
Dr. Schaub's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Schaub) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Pensacola
Browse hematology & oncologys in Pensacola ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in FL
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in FL
Which FL hematology & oncologys receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc..
By company
BeiGene USA, Inc. Payments to Doctors
See all physicians who received payments from BeiGene USA, Inc..
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology